Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. First ...

Novo Nordisk lowered the list price on various insulin products, including pre-filled insulin pens and vials. The company suggested that this would mean patients would pay $25-35 for their insulin.